WELLA Number 8/69 Illumina Coloring

Product Information

Presented data at ASCO, showing support that real-world performance of Galleri is consistent with previous large-scale clinical studies, including the cancer signal detection (CSD) rate and accuracy of the Cancer Signal Origin (CSO) prediction to guide diagnostic workup Illumina's second quarter consolidated revenue grew 8% sequentially from the first quarter, and we saw higher-than-anticipated NovaSeq X shipments," said Charles Dadswell, Interim Chief Executive Officer. "Despite additional placements, we expect our second half revenue to be negatively impacted by customers remaining more cautious in their purchasing, a more protracted recovery in China, and a larger-than-expected temporary decline in high throughput consumables as customers transition to the NovaSeq X. In response, we are increasing customer support for the NovaSeq X and continue to manage our expense base in a disciplined way." All amounts in tables are rounded to the nearest millions, except as otherwise noted. As a result, certain amounts may not recalculate using the rounded amounts provided. Percentages of revenue are calculated based on the revenue of the respective segment. AB, DD8, DD11, IV, KW1 KW14, PA21 PA40, PH17, PH26, PH30, PH35, PH37,PH39, PH41, PH49, PH50, KW15, KW16, KW17, ZE, HS, PA20, PA41, PA49, PA60, PA75, PA77, PA78, KA27, KA28, PH42, PH44, IV40 g) Amounts consist primarily of employee severance costs and lease and other asset impairments related to restructuring activities.

j) Incremental non-GAAP tax expense reflects the tax impact related to the non-GAAP adjustments listed.f) Amount consists of fair value adjustments recognized through Q2 2023 on our Helix contingent value right. Announced results from a retrospective analysis of the interventional PATHFINDER study, demonstrating that in the majority of cases (78%), the test's CSO-directed initial diagnostic evaluation led to a diagnostic resolution Unveiled PrimateAI-3D, an artificial intelligence (AI) algorithm that predicts with unprecedented accuracy disease-causing genetic mutations in patients

View original content: https://www.prnewswire.com/news-releases/illumina-reports-financial-results-for-second-quarter-of-fiscal-year-2023-301897230.html c) Amounts consist primarily of fair value adjustments for our contingent consideration liability related to GRAIL. a) Non-GAAP diluted earnings per share excludes the effects of the pro forma adjustments as detailed above. Non-GAAP diluted earnings per share is a key component of the financial metrics utilized by the company's board of directors to measure, in part, management's performance and determine significant elements of management's compensation. Management has excluded the effects of these items in this measure to assist investors in analyzing and assessing our past and future operating performance. a) See Table 3 included in the "Results of Operations - Non-GAAP" section below for reconciliations of these GAAP and non-GAAP financial measures.

Announced strategic partnership with Pillar Biosciences, Inc. to make Pillar's suite of oncology assays commercially available globally as part of the Illumina portfolio of oncology products